PureTech Health (BATS-CHIXE:PRTCL) - Hisse Senedi Fiyatı, Haberler ve Analizler

PRTCL Stoklara Genel Bakış

PureTech Health plc, Amerika Birleşik Devletleri'nde biyoteknoloji ve farmasötik çözümlerin geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay

PRTCL temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Gelirin yılda 45.42% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $468K )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 13% oranında düşmesi öngörülüyor

PureTech Health plc Rakipler

Oxford Biomedica

LSE:OXB

UK£442.5m

Bioventix

AIM:BVXP

UK£195.7m

Faron Pharmaceuticals Oy

AIM:FARN

UK£149.1m

Genus

LSE:GNS

UK£1.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti PureTech Health
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£1.70
52 Haftanın En Yüksek Seviyesi	UK£2.39
52 Haftanın En Düşük Seviyesi	UK£1.39
Beta	0.99
11 Aylık Değişim	12.55%
3 Aylık Değişim	2.65%
1 Yıllık Değişim	4.28%
33 Yıllık Değişim	-45.21%
5 Yıllık Değişim	-37.81%
Halka arzdan bu yana değişim	26.81%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	PRTCL	GB Biotechs	GB Pazar
7D	-0.9%	0.3%	2.2%
1Y	4.3%	-18.3%	8.0%

Getiri vs. Endüstri: PRTCL geçen yıl % -18.3 oranında getiri sağlayan UK Biotechs sektörünü aştı.

Getiri vs Piyasa: PRTCL geçen yıl % 8 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is PRTCL's price volatile compared to industry and market?
PRTCL volatility
PRTCL Average Weekly Movement	5.7%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: PRTCL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: PRTCL 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	90	Bharatt Chowrira	www.puretechhealth.com

PureTech Health plc, Amerika Birleşik Devletleri'nde biyoteknoloji ve farmasötik çözümlerin geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirket, idiyopatik pulmoner fibrozisi (IPF) tedavi etmek için Faz 2 aşamasında olan LYT-100'ü ve solid tümörleri ve hematolojik maligniteleri tedavi etmek için galektin-9'u hedefleyen ve şu anda Faz 1/2 aşamasında olan bir IgG4 monoklonal antikoru olan LYT-200'ü geliştirmektedir. Ayrıca, endişeli depresyon tedavisi için oral bir allopregnanolone ilacı olan SPT-300'ü; yaygın anksiyete bozukluğu tedavisi için yeni bir agomelatin ön ilacı olan SPT-320'yi ve ruh hali ve diğer nöropsikiyatrik bozuklukların tedavisi için halüsinojenik olmayan bir nöroplastojenin ön ilacı olan SPT-348'i geliştirmektedir.

PureTech Health plc Temel Bilgiler Özeti

PureTech Health'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PRTCL temel i̇stati̇sti̇kler
Piyasa değeri	UK£409.89m
Kazançlar(TTM)	-UK£65.81m
Gelir(TTM)	UK£373.49k

1,097x

P/S Oranı

-6.2x

F/K Oranı

PRTCL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PRTCL gelir tablosu (TTM)
Gelir	US$468.00k
Gelir Maliyeti	US$82.02m
Brüt Kâr	-US$81.55m
Diğer Giderler	US$917.00k
Kazançlar	-US$82.47m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.34
Brüt Marj	-17,425.00%
Net Kâr Marjı	-17,620.94%
Borç/Özkaynak Oranı	40.7%

PRTCL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PRTCL Stoklara Genel Bakış

Ödüller

Risk Analizi

PureTech Health plc Rakipler

LSE:OXB

UK£442.5m

AIM:BVXP

UK£195.7m

AIM:FARN

UK£149.1m

LSE:GNS

UK£1.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

PureTech Health plc Appoints Sandi Peterson to Its Board of Directors

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting

PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

PureTech Health plc Appoints Sandi Peterson to Its Board of Directors

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting

PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in FY 2022)

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

First half 2023 earnings released: US$0.09 loss per share (vs US$0.098 loss in 1H 2022)

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in FY 2021)

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

First half 2022 earnings released: US$0.098 loss per share (vs US$0.26 loss in 1H 2021)

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.021 profit in FY 2020)

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

President recently bought UK£51k worth of stock

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought UK£73k worth of stock

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS

First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020)

President recently bought UK£83k worth of stock

PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202